



# Custom peptide monoclonals

Specialized expertise in anti-peptide antibody  
discovery

# THE COMPANY

BioClonal is a biotechnology company specialized in the development of monoclonal antibodies against peptide epitopes.

Founded in 2022, BioClonal operates from its own R&D laboratories in Zaragoza (Spain) and focuses exclusively on addressing peptide antibody-generation challenges that are difficult to solve using standard immunization approaches.

## Core focus

Monoclonal antibodies against peptides

## Key innovation

A peptide-focused immunization strategy that converts low-immunogenic peptides into reliable antibody targets

## Offerings

Custom monoclonal antibody generation against peptides

Support for diagnostic, therapeutic discovery, and research programs



Solving the Complexity  
of Anti-Peptide  
Antibodies

# The Problem

---

*Up to ~37 % of antibodies generated against peptide targets fail to perform in standard analytical applications, illustrating the inherent challenge of peptide immunogenicity*

## Why current methods fail

**Ultra-low peptide immunogenicity.** Short or low-complexity peptides fail to effectively activate B cells


**Inefficient antigen presentation.** Peptides are poorly processed and presented by antigen-presenting cells

**Unreliable conjugation strategies.** Carrier coupling does not consistently induce strong peptide-specific immunity

**Weak or absent antibody titers.** Standard adjuvants cannot rescue peptide immune responses


**High failure rates.** Extended timelines, increased costs, and loss of confidence in the target

## Our solution



**BioClonal**

# APPLICATIONS



# How we work with partners

---

Developing anti-peptide antibodies for third parties

## 1. Sequence-as-a-Service

 You own everything.

Full ownership of sequences and reagents  
Fixed scope, defined timeline  
50% upfront + milestone payments

 Ideal for CROs, biotechs, pharma with internal R&D

## 2. Co-Development

 We share the journey.

Shared or joint IP rights (negotiable)  
Strategic long-term collaboration  
Flexible payments: upfront, milestones, royalties

 Ideal for early-stage or innovative programs

**A scalable anti-peptide antibody platform for solving challenging peptide targets**

Beyond services:  
building our own assets

Our product portfolio addresses peptide targets relevant across a broad spectrum of diseases, reflecting the versatility of anti-peptide antibodies in complex biological contexts

- NEURODEGENERATIVAS
- DIABETES



**Our own anti-peptide antibody products**



# Proprietary pipeline: Alzheimer



BioClonal is developing a proprietary monoclonal antibody program targeting a **modified form of the A $\beta$ 1–42 peptide**, a peptide species associated with Alzheimer's disease biology.

This anti-peptide monoclonal antibody is being developed internally using BioClonal's proprietary peptide-focused immunization strategy and reflects the company's ability to generate antibodies against highly challenging and biologically relevant peptide targets.

The program is currently in an early development stage, with the objective of progressing into preclinical evaluation.

This program serves as a strategic validation of our anti-peptide antibody platform in a highly complex disease context.

# Internal anti-peptide antibody programs

PROGRAM	TARGET	DEVELOPMENT STAGE			INDICATIONS
		PHASE I: Immunogen design and immunizations	PHASE II: Cell screening or hibridoma	PHASE III: Sequencing and antibody production	
BC 002	AMYLOID BETA 1-16 PEPTIDE				ALZHEIMER DISEASE
BC 002	AMYLOID BETA DERIVED PEPTIDE				ALZHEIMER DISEASE
BC 010	<b>END-RAM. Transmisiones 2025</b> Terapias de RNA, Inmunoterapia y Diagnóstico Avanzado frente a las Resistencias Antimicrobianas. ACTIVIDAD 1				CARBAPENEMASE DIAGNOSTIC
BC 015	<b>END-RAM. Transmisiones 2025</b> Terapias de RNA, Inmunoterapia y Diagnóstico Avanzado frente a las Resistencias Antimicrobianas. ACTIVIDAD 3				EGFR DETECTION FOR DELIVERY
BC 017	INSULINE				DIABETES
BC 018	PEP-C				DIABETES

ENDRAM





**Let's discuss your peptide antibody challenge**

**CONTACT**

[paula@bioclonal.es](mailto:paula@bioclonal.es)

<https://tidycal.com/paulabioclonal/30-minute-meeting>